One to Watch series: new cancer therapy start-up TriMod Therapeutics (Video)
TriMod Therapeutics Ltd is an early stage biotechnology company whose primary R&D; focus is dedicated to developing novel platform technologies to treat cancer and autoimmune diseases including the research and development of treating cognitive disability and mental fatigue.
TriMod was founded on ground-breaking technology originating from the laboratory of Prof. Kingston Mills at Trinity College Dublin. TriMoVav is a pre-clinically validated technology that has the potential to revolutionise the treatment of cancer. Using the patients' own immune system, this innovative technology will specifically target tumours without the need for debilitating chemotherapy. The therapeutic potential is broad and has the ability to tackle several tumour types.
Using a similar technology TriMod is able to utilise and transcend some of the techniques learned within the context of cognitive disability treatment. By evaluating the patients symptoms with Narclopsy, excessive daytime sleepiness and ADHD, TriMod may find innovative methods and specific drug pathways implicated in these disorders. Since late 2015, TriMod has collaborated with the team at www.modapharma.org to help gather customer information regarding their use of the cognitive enhancing drugs Modafinil and Armodafinil. With this vast amount of user data TriMod intends to conduct one of the largest studies of its kind on Modafinil and Armodafinil use offer a broad spectrum of data for further evalutation.